Now, we await the results of experimental exploration of how altered TRIB/COP1 expression affects isoform-specific TRIB abundance, subcellular distribution and downstream functions—a pre-requisite for designing a range of TRIB/COP1-therapeutics to ameliorate obesity-related cancers. The gene discussed is RIBC2; the disease is obesity disorder.